Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Dec 1;190(11):1243–1254. doi: 10.1164/rccm.201406-1095OC

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 by the American Thoracic Society

PMC Copyright notice

Figure 5. — Receptor interacting serine/threonine-protein kinase 3 (RIP3) is released extracellularly after treatment with red blood cells (RBCs). (A) Lung endothelial cells (ECs) supernatant (SN) RIP3 is increased following treatment with RBCs; note the heterogeneity in RIP3 release induced by RBCs. (B) SN densitometry, P = 0.021, total of nine RBC units tested. (C) Lung EC RIP3 decreases following treatment with RBC, addition of necrostatin (Nec)-1–ZVAD attenuates loss of EC RIP3. (D) Supernatant RIP3 is increased following RBC treatment and attenuated with Nec-1, *P = 0.002, ⁺P = 0.045.